554 related articles for article (PubMed ID: 33771664)
21. Cost-effectiveness of adjuvant systemic therapies for patients with high-risk melanoma in Europe: a model-based economic evaluation.
Mulder EEAP; Smit L; Grünhagen DJ; Verhoef C; Sleijfer S; van der Veldt AAM; Uyl-de Groot CA
ESMO Open; 2021 Dec; 6(6):100303. PubMed ID: 34781194
[TBL] [Abstract][Full Text] [Related]
22. [Immune checkpoint inhibitors for treatment of advanced stage melanoma].
Lupu J; Herrscher H; Robert C
Rev Prat; 2020 May; 70(5):471-474. PubMed ID: 33058629
[TBL] [Abstract][Full Text] [Related]
23. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial.
Amaria RN; Prieto PA; Tetzlaff MT; Reuben A; Andrews MC; Ross MI; Glitza IC; Cormier J; Hwu WJ; Tawbi HA; Patel SP; Lee JE; Gershenwald JE; Spencer CN; Gopalakrishnan V; Bassett R; Simpson L; Mouton R; Hudgens CW; Zhao L; Zhu H; Cooper ZA; Wani K; Lazar A; Hwu P; Diab A; Wong MK; McQuade JL; Royal R; Lucci A; Burton EM; Reddy S; Sharma P; Allison J; Futreal PA; Woodman SE; Davies MA; Wargo JA
Lancet Oncol; 2018 Feb; 19(2):181-193. PubMed ID: 29361468
[TBL] [Abstract][Full Text] [Related]
24. Treatment of Stage III Resectable Melanoma-Adjuvant and Neoadjuvant Approaches.
Tarhini AA; Castellano E; Eljilany I
Cancer J; 2024 Mar-Apr 01; 30(2):54-70. PubMed ID: 38527258
[TBL] [Abstract][Full Text] [Related]
25. Nivolumab versus placebo as adjuvant therapy for resected stage III melanoma: a propensity weighted indirect treatment comparison and number needed to treat analysis for recurrence-free survival and overall survival.
Weber JS; Poretta T; Stwalley BD; Sakkal LA; Du EX; Wang T; Chen Y; Wang Y; Betts KA; Shoushtari AN
Cancer Immunol Immunother; 2023 Apr; 72(4):945-954. PubMed ID: 36197494
[TBL] [Abstract][Full Text] [Related]
26. Adjuvant Therapy for High-Risk Melanoma: An In-Depth Examination of the State of the Field.
Eljilany I; Castellano E; Tarhini AA
Cancers (Basel); 2023 Aug; 15(16):. PubMed ID: 37627153
[TBL] [Abstract][Full Text] [Related]
27. Cost-Effectiveness Analysis of Adjuvant Therapy for BRAF-Mutant Resected Stage III Melanoma in Medicare Patients.
Mojtahed SA; Boyer NR; Rao SA; Gajewski TF; Tseng J; Turaga KK
Ann Surg Oncol; 2021 Dec; 28(13):9039-9047. PubMed ID: 34129153
[TBL] [Abstract][Full Text] [Related]
28. Comparison of efficacy and tolerability of adjuvant therapy for resected high-risk stage III-IV cutaneous melanoma: a systemic review and Bayesian network meta-analysis.
Ba H; Zhu F; Zhang X; Mei Z; Zhu Y
Ther Adv Med Oncol; 2023; 15():17588359221148918. PubMed ID: 36743526
[TBL] [Abstract][Full Text] [Related]
29. Outcome of adjuvant immunotherapy in a real-world nation-wide cohort of patients with melanoma.
Holmstroem RB; Pedersen S; Jurlander R; Madsen K; Donia M; Ruhlmann CH; Schmidt H; Haslund CA; Bastholt L; Svane IM; Ellebaek E
Eur J Cancer; 2024 May; 202():114023. PubMed ID: 38518533
[TBL] [Abstract][Full Text] [Related]
30. Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma.
Long GV; Hauschild A; Santinami M; Atkinson V; Mandalà M; Chiarion-Sileni V; Larkin J; Nyakas M; Dutriaux C; Haydon A; Robert C; Mortier L; Schachter J; Schadendorf D; Lesimple T; Plummer R; Ji R; Zhang P; Mookerjee B; Legos J; Kefford R; Dummer R; Kirkwood JM
N Engl J Med; 2017 Nov; 377(19):1813-1823. PubMed ID: 28891408
[TBL] [Abstract][Full Text] [Related]
31. Adjuvant Systemic Therapies for Resected Stages III and IV Melanoma: A Multi-Center Retrospective Clinical Study.
Rigo R; Ding PQ; Batuyong E; Cheung WY; Walker J; Monzon JG; Cheng T
Oncologist; 2024 Jan; 29(1):57-66. PubMed ID: 37648247
[TBL] [Abstract][Full Text] [Related]
32. Comparative efficacy and safety of dabrafenib in combination with trametinib versus competing adjuvant therapies for high-risk melanoma.
Sharma R; Koruth R; Kanters S; Druyts E; Tarhini A
J Comp Eff Res; 2019 Dec; 8(16):1349-1363. PubMed ID: 31778073
[No Abstract] [Full Text] [Related]
33. Systemic Therapy for Melanoma: ASCO Guideline Update.
Seth R; Agarwala SS; Messersmith H; Alluri KC; Ascierto PA; Atkins MB; Bollin K; Chacon M; Davis N; Faries MB; Funchain P; Gold JS; Guild S; Gyorki DE; Kaur V; Khushalani NI; Kirkwood JM; McQuade JL; Meyers MO; Provenzano A; Robert C; Santinami M; Sehdev A; Sondak VK; Spurrier G; Swami U; Truong TG; Tsai KK; van Akkooi A; Weber J
J Clin Oncol; 2023 Oct; 41(30):4794-4820. PubMed ID: 37579248
[TBL] [Abstract][Full Text] [Related]
34. Combined ipilimumab and nivolumab first-line and after BRAF-targeted therapy in advanced melanoma.
Mason R; Dearden HC; Nguyen B; Soon JA; Smith JL; Randhawa M; Mant A; Warburton L; Lo S; Meniawy T; Guminski A; Parente P; Ali S; Haydon A; Long GV; Carlino MS; Millward M; Atkinson VG; Menzies AM
Pigment Cell Melanoma Res; 2020 Mar; 33(2):358-365. PubMed ID: 31587511
[TBL] [Abstract][Full Text] [Related]
35. Immune checkpoint inhibitors in adjuvant setting after radical resection of melanoma: a meta-analysis of the pivotal trials.
Bersanelli M; Petrelli F; Buti S; Stanganelli I
Hum Vaccin Immunother; 2022 May; 18(3):1902723. PubMed ID: 33881961
[TBL] [Abstract][Full Text] [Related]
36. A systematic literature review and network meta-analysis of effectiveness and safety outcomes in advanced melanoma.
Franken MG; Leeneman B; Gheorghe M; Uyl-de Groot CA; Haanen JBAG; van Baal PHM
Eur J Cancer; 2019 Dec; 123():58-71. PubMed ID: 31670077
[TBL] [Abstract][Full Text] [Related]
37. 25 Years of Adjuvant Therapy in Melanoma: A Perspective on Current Approvals and Insights into Future Directions.
Truong TG; Kennedy LB; Patel SP
Curr Oncol Rep; 2022 Apr; 24(4):533-542. PubMed ID: 35192117
[No Abstract] [Full Text] [Related]
38. Neoadjuvant immunotherapy with combined ipilimumab and nivolumab in patients with melanoma with primary or in transit disease.
Weber J; Glutsch V; Geissinger E; Haug L; Lock JF; Schneider F; Kneitz H; Goebeler M; Schilling B; Gesierich A
Br J Dermatol; 2020 Sep; 183(3):559-563. PubMed ID: 31773720
[TBL] [Abstract][Full Text] [Related]
39. PIVOT-12: a phase III study of adjuvant bempegaldesleukin plus nivolumab in resected stage III/IV melanoma at high risk for recurrence.
Eggermont AM; Ascierto PA; Khushalani NI; Schadendorf D; Boland G; Weber J; Lewis KD; Johnson D; Rivalland G; Khattak A; Majem M; Gogas H; Long GV; Currie SL; Chien D; Tagliaferri MA; Carlino MS; Diab A
Future Oncol; 2022 Mar; 18(8):903-913. PubMed ID: 35073733
[TBL] [Abstract][Full Text] [Related]
40. Systemic adjuvant therapy for high-risk cutaneous melanoma.
Kobeissi I; Tarhini AA
Ther Adv Med Oncol; 2022; 14():17588359221134087. PubMed ID: 36324735
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
